Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The uric acid degradation bifunctional protein, commonly known as urate oxidase or uricase, is a key enzyme in the purine catabolic pathway. It catalyzes the oxidation of uric acid to 5-hydroxyisourate, which is further degraded to allantoin—a more water-soluble compound that can be easily excreted from the body. This enzymatic activity is crucial for maintaining low levels of uric acid and preventing its accumulation. In humans loss of the enzyme's activity leads to increased risk for gout and other hyperuricemia-related pathologies, therefore recombinant forms are used as therapeutics.
Catalyzes the oxidation of uric acid to 5-hydroxyisourate, which is further degraded to allantoin
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Uric Acid Degradation Bifunctional Protein (None).